Champix is the first new prescription aid to smoking cessation treatment in nearly a decade. Pfizer discovered and developed Champix specifically as an aid to smoking cessation through its unique mechanism of action targeting the specific receptor to which nicotine binds. Champix is believed to work by reducing the severity of the smoker’s urge to smoke.
The medication, varenicline, with trade name Chantix (varenicline) in the United States, received U.S. Food and Drug Administration approval as an aid to smoking cessation in May 2006. In the European Union, Champix received marketing authorization in September 2006 for use as a smoking cessation aid. For a patient prescribed Champix or Chantix, Pfizer also offers behavioral support, a personalized online interactive program to help smokers quit, at no extra cost. In clinical trials, varenicline was generally well tolerated with overall discontinuation rates similar to placebo. The most frequent side effects included nausea, headache, trouble sleeping and changes in dreaming.
(BUSINESS WIRE)--Pfizer Inc
More: HERE
About CHANTIX
A non-nicotine pill
CHANTIX™ (varenicline) is non-nicotine prescription medicine specifically developed to help adults quit smoking.
How is CHANTIX different from other smoking cessation products?
CHANTIX contains no nicotine, but it targets the same receptors that nicotine does. CHANTIX is believed to block nicotine from these receptors. It is the only prescription treatment of its kind.
Studies show: At the end of 12 weeks of CHANTIX, 44% were able to quit smoking. It also helped reduce the urge to smoke.
CHANTIX has been proven to be more effective in helping smokers quit than Zyban®. The average person in these studies had been a smoker for more than 24 years. The trials involved a mix of men and women who smoked on average 10 or more cigarettes a day.
More: HERE
